‘Sunshine Genetics Act’ Advances in Florida, Taking a Bold Steps for Pediatric Rare Disease Research and Treatment

A new bill aimed at advancing pediatric rare disease research is making its way through the Florida House. Just clearing its first committee hearing Tuesday, in a 17-0 vote, the Sunshine Genetics Act (HB 907), introduced by Representatives Adam Anderson and Erin Owen, establishes the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine. The bill outlines key initiatives to improve diagnosis, treatment, and care for children affected by rare genetic disorders.

The legislation codifies the Florida Institute for Pediatric Rare Diseases, positioning it as a statewide resource for research and clinical care. The mission of the Institute is to enhance the quality of life for children and families impacted by rare diseases through research, advanced diagnostic tools, and multidisciplinary care. The Institute will focus on conducting research to better understand the causes, mechanisms, and potential treatments for pediatric rare diseases. It will also work to develop advanced diagnostic and genetic screening tools to enable healthcare providers to identify rare diseases in newborns and children more rapidly and accurately. In addition to research and diagnostics, the Institute will provide comprehensive care and support for families and caregivers of children with rare diseases, as well as focus on educating healthcare professionals in the field.

One of the most notable components of the Sunshine Genetics Act is the establishment of the Sunshine Genetics Pilot Program. The program will offer genetic screening for newborns, including whole genome sequencing, for a period of five years. The pilot program will be opt-in, with parental consent required for participation. The program aims to detect rare diseases early, providing clinical findings to both the newborn’s healthcare practitioner and the parents. The Institute will maintain a secure database for pilot program data, and deidentified data will be shared with the Sunshine Genetics Consortium for further research.

The bill also creates the Sunshine Genetics Consortium, a network of researchers, geneticists, and healthcare professionals from Florida’s state universities and children’s hospitals. The Consortium will collaborate with leaders in the genetic industry to further develop cutting-edge genetic and precision medicine. The Consortium’s responsibilities include integrating state-of-the-art genomic sequencing technologies, advancing genetic research, and developing educational opportunities for clinicians on genomic tools. The Consortium will also seek funding from nonprofit organizations and private industry to expand the Sunshine Genetics Pilot Program and support genetic screenings by institutions that are part of the oversight board.

To manage these efforts, the bill calls for the creation of an oversight board for the Consortium. The board will consist of representatives from top Florida universities and will include appointees from the Governor, the President of the Senate, and the Speaker of the House of Representatives. The board will meet at least twice a year to review progress and oversee the Consortium’s activities.

The fiscal impact of the bill includes an appropriation of $5 million in recurring funds for the 2025-2026 fiscal year to support the Florida Institute for Pediatric Rare Diseases. An additional $20 million in nonrecurring funds will be allocated to support the implementation of the Sunshine Genetics Pilot Program.

This legislation aims to significantly improve early detection and treatment of rare pediatric diseases in Florida, providing critical support to affected families and advancing genetic research in the state. The bill is set to take effect on July 1, 2025, with the Sunshine Genetics Pilot Program launching shortly thereafter.